Skip to main content

Advertisement

Figure 5 | Cell & Bioscience

Figure 5

From: DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity

Figure 5

Comparison of OVA-specific CD8+ T cell responses induced by different forms of OVA-specific vaccines. 5 to 8 weeks old C57BL/6 mice (5 per group) were vaccinated with HPV-16 pseudovirions carrying OVA (HPV-16/OVA psV) containing pcDNA3-OVA (50 ng) subcutaneously (s.c.), or OVA8 (aa257-264) (15 μg) in incomplete Freund's adjuvant (IFA), or OVA30 (aa241-270) (50 μg) in IFA, or OVA protein (50 μg) in IFA s.c., or OVA8-pulsed bone marrow-derived dendritic cells (BMDC) (5 × 105 cells/mouse). Mice were boosted once after 7 days with the same dose and regimen. At the time of boost, another group of naïve mice were vaccinated with OVA-expressing vaccinia viruses (OVA-VV) (1 × 107 pfu) intraperitoneally. Splenocytes were collected one week after last vaccination, and stimulated with OVA MHC class I peptide SIINFEKL (1 μg/ml) at the presence of GolgiPlug. The OVA-specific CD8+ T cells were then analyzed by staining surface CD8 and intracellular IFN-γ. A. Representative flow cytometry data. B. Graphical representation of the number of OVA-specific CD8+ T cells per 3 × 105 splenocytes. Data expressed as means ± standard deviations (SD) are representative of at least two different experiments.

Back to article page